Yale Cancer Center, Yale School of Medicine, CT, United States.
Yale Cancer Center, Yale School of Medicine, CT, United States.
Transfus Apher Sci. 2022 Apr;61(2):103304. doi: 10.1016/j.transci.2021.103304. Epub 2021 Oct 30.
Chronic red blood cell transfusions reduce acute care utilization for sickle cell disease (SCD) pain. However, little is known about whether chronic transfusions treat or prevent the development of non-crisis pain. We investigated patient-report of pain in adults with SCD receiving chronic exchange transfusions (CET) compared to adults not on CET with similar disease characteristics.
Eleven participants receiving chronic exchange transfusion (CET) for at least one year were compared to 33 participants not receiving CET. Participants completed validated patient-reported outcomes regarding pain impact and quality of life at regularly scheduled visits or before CET. One year of health care utilization and opioid prescriptions were examined.
After 1:1 propensity matching was performed for age, genotype, WBC and neutrophil counts, patients on CET had lower Pain Impact scores (-5.1, p = 0.03) and higher Neuropathic (7.4, p < 0.001) and Nociceptive Pain Quality (3.7, p < 0.001) scores, all indicating worse pain. However, CET was associated with a reduction in annual all cause admissions (-3.1, p < 0.001), length of stay (-2.1 days, p < 0.001) and ED visits (-2.7, p < 0.001). CET was not associated with differences in opioids dispensed.
After adjusting for disease characteristics, CET was associated with worse pain impact and neuropathic and nociceptive pain quality, lower health care utilization and with similar levels of opioids dispensed. This data suggest that CET may reduce hospitalizations for acute pain but may not adequately treat nociceptive or neuropathic pain in SCD.
慢性红细胞输注可减少镰状细胞病(SCD)疼痛的急性护理利用。然而,对于慢性输血是否治疗或预防非危机性疼痛的发展,知之甚少。我们调查了接受慢性交换输血(CET)的 SCD 成年患者与具有相似疾病特征但未接受 CET 的成年患者的报告疼痛。
将至少接受一年慢性交换输血(CET)的 11 名参与者与未接受 CET 的 33 名参与者进行比较。参与者在定期就诊或 CET 之前完成了关于疼痛影响和生活质量的经过验证的患者报告结果。检查了一年的医疗保健利用和阿片类药物处方。
在进行了年龄、基因型、白细胞和中性粒细胞计数的 1:1 倾向匹配后,接受 CET 的患者的疼痛影响评分较低(-5.1,p = 0.03),神经痛(7.4,p < 0.001)和伤害性疼痛质量(3.7,p < 0.001)评分较高,所有这些都表明疼痛更严重。然而,CET 与全因入院减少(-3.1,p < 0.001)、住院时间减少(-2.1 天,p < 0.001)和急诊就诊减少(-2.7,p < 0.001)有关。CET 与阿片类药物的配给量无差异。
在调整疾病特征后,CET 与疼痛影响更大、神经痛和伤害性疼痛质量更高、医疗保健利用率更低有关,同时配给的阿片类药物水平相似。这些数据表明,CET 可能减少急性疼痛的住院治疗,但可能无法充分治疗 SCD 中的伤害性或神经痛。